Purification and identification of High Molecular Weight Products formed during storage of neutral formulation of human insulin

Pharmaceutical Research

Volumn 32, Issue 6, 2015, Pages 2072-2085

  Hjorth, Christian Fogt ^a,b   Hubálek, František ^a   Andersson, Jonatan ^a   Poulsen, Christian ^a   Otzen, Daniel ^b   Naver, Helle ^a  

^a NOVO NORDISK A S   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

High Molecular Weight Products (HMWP); Human insulin; Mass spectrometry; Reverse phase chromatography; Size exclusion chromatography

Indexed keywords

ACID ANHYDRIDE; HIGH MOLECULAR WEIGHT PRODUCT; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; NEUTRAL INSULIN; UNCLASSIFIED DRUG; 4-CRESOL; AMINE; ANTIDIABETIC AGENT; CRESOL; INSULIN, NEUTRAL; PIG INSULIN; ZINC;

ARTICLE; DRUG FORMULATION; DRUG STORAGE; GEL PERMEATION CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; AMINO ACID SEQUENCE; CHEMISTRY; DRUG CONTAMINATION; DRUG STABILITY; HUMAN; MEDICINAL CHEMISTRY; MOLECULAR WEIGHT; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; SIZE EXCLUSION CHROMATOGRAPHY; TEMPERATURE; TIME FACTOR;

AMINES; AMINO ACID SEQUENCE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, REVERSE-PHASE; CRESOLS; DRUG CONTAMINATION; DRUG STABILITY; DRUG STORAGE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, REGULAR, HUMAN; INSULIN, REGULAR, PORK; MOLECULAR WEIGHT; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; TANDEM MASS SPECTROMETRY; TEMPERATURE; TIME FACTORS; ZINC;

EID: 84934942708     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1600-3     Document Type: Article

References (39)

1. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-88.
2. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298-306.
3. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structureimmunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21(6):897-903.
4. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75.
5. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006;95(5):1084-96.
6. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res. 2011;28(10):2393-402.
7. Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity. 2007;40(2):131-7.
8. JarsMU, Hvass A, Waaben D. Insulin aspart (AspB28 human insulin) derivatives formed in pharmaceutical solutions. Pharm Res. 2002;19(5):621-8.
9. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98(4):1201-5.
10. Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schöneich C, Winter G, et al. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci. 2012;101(3):946-54.
11. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci. 2010;99(8):3302-21.
12. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):354-87.
13. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):501-7.
14. Insulin human. European pharmacopoeia. 7 ed. Strasbourg: Council of Europe; 2013
15. Brange J, Hallund O, Sørensen E. Chemical stability of insulin. 5. Isolation, characterization and identification of insulin transformation products. Acta Pharm Nord. 1992;4(4):223-32.
16. Maislos M, Mead PM, Gaynor DH, Robbins DC. The source of the circulating aggregate of insulin type I diabetic patients is therapeutic insulin. J Clin Invest. 1986;77(3):717-23.
17. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16(3):155-65.
18. Ratner ER, Phillips TM, Steiner M. Persistent cutaneous insulin allergy resulting from high molecular weight insulin aggregates. Diabetes. 1990;39(6):728-33.
19. Robbins DC, Mead PM. Free covalent aggregates of therapeutic insulin in blood of insulin-dependent diabetics. Diabetes. 1987;36(2):147-51.
20. Brems DN, Brown PL, Bryant C, Chance RE, Green LK, Long HB, et al. Improved insulin stability through amino acid substitution. Protein Eng. 1992;5(6):519-25.
21. Darrington RT, Anderson BD. Evidence for a common intermediate in insulin deamidation and covalent dimer formation: effects of pH and aniline trapping in dilute acidic solutions. J Pharm Sci. 1995;84(3):275-82.
22. Darrington RT, Anderson BD. Effects of insulin concentration and self-association on the partitioning of Its A-21 cyclic anhydride intermediate to desamido insulin and covalent dimer. Pharm Res. 1995;12(7):1077-84.
23. DeHart MP, Anderson BD. Kinetics and mechanisms of deamidation and covalent amide-linked adduct formation in amorphous lyophiles of a model asparagine-containing peptide. Pharm Res. 2012;29(10):2722-37.
24. Torosantucci R, Mozziconacci O, Sharov V, Schöneich C, Jiskoot W. Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via michael addition to tyrosine oxidation products. Pharm Res. 2012;29(8):2276-93.
25. Printz M, Friess W. Simultaneous detection and analysis of protein aggregation and protein unfolding by size exclusion chromatography with post column addition of fluorescent dye BisANS. J Pharm Sci. 2012;101(2):826-37.
26. Tantipolphan R, Romeijn S, Engelsman J, Torosantucci R, Rasmussen T, Jiskoot W. Elution behavior of insulin on highperformance size exclusion chromatography at neutral pH. J Pharm Biomed Anal. 2010;52(2):195-202.
27. Carpenter FH. Relationship of structure to biological activity of insulin as revealed by degradative studies. Am J Med. 1966;40(5): 750-8.
28. Brange J, Havelund S, Hougaard P. Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res. 1992;9(6): 727-34.
29. Hawe A, Wiggenhorn M, Van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913.
30. Huus K, Havelund S, Olsen HB, Van de Weert M, Frokjaer S. Thermal dissociation and unfolding of insulin. Biochemistry. 2005;44(33):11171-7.
31. Darrington RT, Anderson BD. The role of intramolecular nucleophilic catalysis and the effects of self-association on the deamidation of human insulin at low pH. Pharm Res. 1994;11(6):784-93.
32. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-94.
33. Poulsen C, Jacobsen D, Palm L. Effect of ethylenediamine on chemical degradation of insulin aspart in pharmaceutical solutions. Pharm Res. 2008;25(11):2534-44.
34. Markussen J, Diers I, Hougaard P, Langkjær L, Norris K, Snel L, et al. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng. 1988;2(2):157-66.
35. Teska BM, Alarcón J, Pettis RJ, Randolph TW, Carpenter JF. Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature. J Pharm Sci. 2014;103(8):2255-67.
36. Brange J, Langkjær L. Chemical stability of insulin. 3. Influence of excipients, formulation, and pH. Acta Pharm Nord. 1992;4(4):149-58.
37. Derewenda U, Derewenda Z, Dodson EJ, Dodson GG, Reynolds CD, Smith GD, et al. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature. 1989;338(6216):594-6.
38. Kaarsholm NC, Ko HC, Dunn MF. Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin and miniproinsulin. Biochemistry. 1989;28(10):4427-35.
39. Peters B, Trout BL. Asparagine deamidation: pH-dependent mechanism from density functional theory. Biochemistry. 2006;45(16): 5384-92.